BibTex RIS Kaynak Göster

Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up

Yıl 2015, Cilt: 5 Sayı: 01, 32 - 35, 30.04.2015
https://doi.org/10.5799/ahinjs.02.2015.01.0172

Öz

Boceprevir is a NS3/4A hepatitis C virus (HCV) protease inhibitor, used in combination with peginterferon and ribavirin to treat HCV. Boceprevir undergoes extensive metabolism via cytochrome P450-mediated oxidation and ketoreduction by cytosolic aldo-keto reductases. Amlodipine has been used for the treatment of patients with hypertension and also metabolised through cytochrome P450 pathway. Here, we presented a case of boceprevir and amlodipine interaction in a patient with chronic HCV and her echocardiography and electrocardiographic follow-up results.

Kaynakça

  • Merck & Co Inc. Package insert: Victrelis (boceprevir) cap- sules. Available at: http://www.merck.com/product/usa/pi_ circulars/v/victrelis/victrelis_pi.pdf Accessed 16 March 2014.
  • Ghosal A, Yuan Y, Tong W, et al. and Alton KB Characteriza- tion of human liver enzymes involved in the biotransforma- tion of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39:510-521.
  • Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interac- tions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012;11:179–185.
  • Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Ca- nadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol. 2010;26:249-258.
  • Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a Euro- pean Society of Hypertension Task Force document. J Hy- pertens. 2009;27:2121-2158.
  • Henneman A, Thornby KA. Risk of hypotension with concomi- tant use of calcium-channel blockers and macrolide antibiot- ics. Am J Health Syst Pharm. 2012;69:1038–1043.
  • Tungol A.et al. Formulary Management of the Protease Inhibi- tors Boceprevir
  • and Telaprevir for Chronic Hepatitis C VirusJournal of Managed Care Pharmacy. 2011;17:685-694.
  • U.S. Food and Drug Administration. FDA news release. FDA approves Victrelis for hepatitis C. May 13, 2011. Available at : http://www.fda.gov/NewsEvents/Newsroom/PressAn- nouncements/ucm255390.htm Accessed 15 March 2014.
  • Victrelis (boceprevir) capsules. Merck. May 2011. Avail- able at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2011/202258lbl.pdf Accessed 15 March 2014.
  • Merck & Co Inc. Package insert: Victrelis (boceprevir) cap- sules. Available
  • at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/vic- trelis_pi.pdf
  • Accessed 16 March 2014.
  • Tóth K. PIANIST Investigators. Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyper- tensive patients). Am J Cardiovasc Drugs. 2014;14:137-145.
  • J Bramlage P, Zemmrich C, Gansz A, et al. Daytime sys- tolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with un- controlled essential hypertension (SEVICONTROL-2).Clin Hypertens (Greenwich). 2014;16:41-46.
  • Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel block- er-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;18;310:2544-2553.
  • Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug- drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacoki- net. 2013;52:815-831.

Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up

Yıl 2015, Cilt: 5 Sayı: 01, 32 - 35, 30.04.2015
https://doi.org/10.5799/ahinjs.02.2015.01.0172

Öz

Boceprevir, Hepatit C virüs (HCV) enfeksiyonunun tedavisinde peginterferon ve ribavirin ile kombine edilerek kullanılan NS3/4A HCV proteaz inhibitörüdür. Boceprevir, büyük çoğunlukla sitokrom P450 ilişkili oksidasyon ve sitozolik aldo-keto redüktaz ile ketoredüksiyon yoluyla metabolize olur. Amlodipin hipertansiyonu olan hastaların tedavisinde kullanılmaktadır ve amlodipin de sitokrom P450 yoluyla metabolize olur. Bu yazıda, boceprevir ve amlodipin kronik HCV enfeksiyonu olan bir hastadaki etkileşimini ve bu hastanın ekokardiyografik ve elektrokardiyografik takip sonuçlarını sunduk

Kaynakça

  • Merck & Co Inc. Package insert: Victrelis (boceprevir) cap- sules. Available at: http://www.merck.com/product/usa/pi_ circulars/v/victrelis/victrelis_pi.pdf Accessed 16 March 2014.
  • Ghosal A, Yuan Y, Tong W, et al. and Alton KB Characteriza- tion of human liver enzymes involved in the biotransforma- tion of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39:510-521.
  • Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interac- tions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012;11:179–185.
  • Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Ca- nadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol. 2010;26:249-258.
  • Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a Euro- pean Society of Hypertension Task Force document. J Hy- pertens. 2009;27:2121-2158.
  • Henneman A, Thornby KA. Risk of hypotension with concomi- tant use of calcium-channel blockers and macrolide antibiot- ics. Am J Health Syst Pharm. 2012;69:1038–1043.
  • Tungol A.et al. Formulary Management of the Protease Inhibi- tors Boceprevir
  • and Telaprevir for Chronic Hepatitis C VirusJournal of Managed Care Pharmacy. 2011;17:685-694.
  • U.S. Food and Drug Administration. FDA news release. FDA approves Victrelis for hepatitis C. May 13, 2011. Available at : http://www.fda.gov/NewsEvents/Newsroom/PressAn- nouncements/ucm255390.htm Accessed 15 March 2014.
  • Victrelis (boceprevir) capsules. Merck. May 2011. Avail- able at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2011/202258lbl.pdf Accessed 15 March 2014.
  • Merck & Co Inc. Package insert: Victrelis (boceprevir) cap- sules. Available
  • at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/vic- trelis_pi.pdf
  • Accessed 16 March 2014.
  • Tóth K. PIANIST Investigators. Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyper- tensive patients). Am J Cardiovasc Drugs. 2014;14:137-145.
  • J Bramlage P, Zemmrich C, Gansz A, et al. Daytime sys- tolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with un- controlled essential hypertension (SEVICONTROL-2).Clin Hypertens (Greenwich). 2014;16:41-46.
  • Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel block- er-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;18;310:2544-2553.
  • Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug- drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacoki- net. 2013;52:815-831.
Toplam 17 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Olgu Sunumu
Yazarlar

Çiğdem Kader Bu kişi benim

Hüseyin Ede Bu kişi benim

Ayşe Erbay Bu kişi benim

Alirıza Erbay Bu kişi benim

Yayımlanma Tarihi 30 Nisan 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 5 Sayı: 01

Kaynak Göster

APA Kader, Ç., Ede, H., Erbay, A., Erbay, A. (2015). Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up. Journal of Microbiology and Infectious Diseases, 5(01), 32-35. https://doi.org/10.5799/ahinjs.02.2015.01.0172
AMA Kader Ç, Ede H, Erbay A, Erbay A. Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up. J Microbil Infect Dis. Mart 2015;5(01):32-35. doi:10.5799/ahinjs.02.2015.01.0172
Chicago Kader, Çiğdem, Hüseyin Ede, Ayşe Erbay, ve Alirıza Erbay. “Drug Interaction of Bocepravir and Amlodipine in a Patient With Hepatitis C: A Cardiovascular Follow-up”. Journal of Microbiology and Infectious Diseases 5, sy. 01 (Mart 2015): 32-35. https://doi.org/10.5799/ahinjs.02.2015.01.0172.
EndNote Kader Ç, Ede H, Erbay A, Erbay A (01 Mart 2015) Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up. Journal of Microbiology and Infectious Diseases 5 01 32–35.
IEEE Ç. Kader, H. Ede, A. Erbay, ve A. Erbay, “Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up”, J Microbil Infect Dis, c. 5, sy. 01, ss. 32–35, 2015, doi: 10.5799/ahinjs.02.2015.01.0172.
ISNAD Kader, Çiğdem vd. “Drug Interaction of Bocepravir and Amlodipine in a Patient With Hepatitis C: A Cardiovascular Follow-up”. Journal of Microbiology and Infectious Diseases 5/01 (Mart 2015), 32-35. https://doi.org/10.5799/ahinjs.02.2015.01.0172.
JAMA Kader Ç, Ede H, Erbay A, Erbay A. Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up. J Microbil Infect Dis. 2015;5:32–35.
MLA Kader, Çiğdem vd. “Drug Interaction of Bocepravir and Amlodipine in a Patient With Hepatitis C: A Cardiovascular Follow-up”. Journal of Microbiology and Infectious Diseases, c. 5, sy. 01, 2015, ss. 32-35, doi:10.5799/ahinjs.02.2015.01.0172.
Vancouver Kader Ç, Ede H, Erbay A, Erbay A. Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up. J Microbil Infect Dis. 2015;5(01):32-5.